What is Apollomics?
Apollomics is a clinical-stage biotechnology company dedicated to the discovery and development of innovative oncology therapies. The company distinguishes itself through a focus on combination treatment approaches, leveraging a deep understanding of molecular biology to address the complexities of cancer progression. By targeting specific pathways and immune-related mechanisms, Apollomics aims to provide more effective therapeutic options for patients facing limited treatment alternatives. The company's operational model integrates rigorous scientific research with strategic clinical development, ensuring that its drug candidates are positioned to meet the high standards required for regulatory approval and commercial success in the global healthcare market.
How much funding has Apollomics raised?
Apollomics has raised a total of $250.9M across 6 funding rounds:
Angel/Seed
$5M
Series A
$9.8M
Series B
$100M
Series C
$124.2M
Debt
$2M
Stock/Share Issuance
$10M
Angel/Seed (2016): $5M, investors not publicly disclosed
Series A (2016): $9.8M led by OrbiMed Asia
Series B (2019): $100M, investors not publicly disclosed
Series C (2020): $124.2M featuring Ping An Capital
Debt (2026): $2M, investors not publicly disclosed
Stock/Share Issuance (2026): $10M, investors not publicly disclosed
Key Investors in Apollomics
OrbiMed Asia
OrbiMed is a premier healthcare-focused investment firm that manages capital across the entire spectrum of the life sciences industry, from early-stage ventures to established commercial entities. Their team provides deep operational expertise and strategic guidance to support the growth of innovative biotech companies.
Ping An Capital
Ping An Capital is a prominent investment arm focused on identifying high-growth opportunities within the healthcare and technology sectors, providing significant financial backing to support enterprise-level scaling.
Undisclosed Investor
An undisclosed institutional investor participating in the funding round to support the company's ongoing clinical development and strategic growth initiatives.
What's next for Apollomics?
Looking ahead, the strategic deployment of the recent $10M will likely focus on advancing the company's lead assets through critical clinical milestones. With a solid foundation of capital, Apollomics is well-positioned to expand its research and development capabilities, potentially exploring new therapeutic modalities or broadening its pipeline to address additional oncology indications. The company's focus will remain on executing its clinical trials with precision, while simultaneously exploring potential partnerships that could enhance its market reach and commercialization strategy. As the biotech sector continues to evolve, Apollomics' ability to maintain its momentum will be contingent upon its success in translating scientific innovation into tangible clinical benefits for patients, thereby creating long-term value for its stakeholders and the broader medical community.
See full Apollomics company page
